海外の治験の状況「前立腺癌」での検索結果
25件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment
- Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom, United States
- 2016-09-15
Authorised
- A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate Cancer
- Metastatic Hormone-Naive Prostate Cancer (mHNPC) MedDRA version: 19.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2012-09-11
Authorised
- Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)
- metastatic Castrate Resistant Prostate Cancer (mCRPC).;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Greece, Hong Kong, Hungary, India, Italy, Korea, Republic of, Malaysia, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Tunisia, Ukraine, United Kingdom, United States
- 2014-03-26
Authorised
- A study investigating the safety of radium-223 dichloride with abiraterone acetate and prednisone/prednisolone given to patients with castration-resistant prostate cancer that has spread to bone, and who never had chemotherapy before.
- Asymptomatic or mildly symptomatic chemotherapy-naïve bone predominant metastatic castration-resistant prostate cancer br>MedDRA version: 16.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, China, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom, United States
- 2014-01-13
Authorised
- [18F] Dihyro-testosterone(FDHT) PET/CT- A novel Imaging technique in Patients with Porgressive Prostate Cancer
- Progressive Prostate cancer br>MedDRA version: 18.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Netherlands, United Kingdom, United States
- 2015-10-23
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, Finland, France, Germany, Greece, Poland, Slovakia, South Africa, United Kingdom, United States
- 2017-12-22
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-09-12
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-08-22
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, Finland, France, Germany, Greece, Poland, Slovakia, South Africa, United Kingdom, United States
- 2018-07-24
Authorised
- A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
- Metastatic Castrate-Resistant Prostate Cancer br>MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Costa Rica, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-05-04